Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd, a radiopharmaceutical company focused on cancer treatment, has reported a significant revenue increase of 49% in their recent Preliminary Final Report for the year ending June 30, 2024, though the company’s net loss also grew by 72% to $42.3 million. No dividends were paid or declared during the financial period, and the net tangible assets per share rose to 46.9 cents from 26.5 cents in the previous year.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.